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Aim: To examine the rates of all-cause mortality and heart failure (HF) readmission in patients 
hospitalized with decompensated HF according to HF duration – new-onset HF and worsening of 
chronic HF. 
Methods and Results: In this nationwide observational cohort study, 17,176 patients were included 
at first hospital admission for HF in the period 2013-2015 using data from Danish nationwide 
registries. In total, 8,860 (51.6%) patients were admitted with new-onset HF and 8,316 (48.4%) with 
worsening of chronic HF. Patients with worsening of chronic HF were characterized by a greater 
comorbidity burden compared with patients with new-onset HF. The rates of outcomes were 
examined by multivariable Cox regression models, adjusted for age, sex, and comorbidity. 
Worsening of chronic HF was associated with a higher rate of the composite endpoint of all-cause 
mortality or HF readmission (hazard ratio [HR] 1.37 [95% CI, 1.31-1.43]), all-cause mortality (HR 
1.22 [95% CI, 1.16-1.28]), and HF readmission (HR 1.81 [95% CI, 1.69-1.93]) compared with new-
onset HF. There was an interaction between atrial fibrillation (AF), HF duration, and outcome: In 
worsening of chronic HF, the rate of the composite endpoint was higher in patients with AF 
compared with those without (HR 1.12 [95% CI, 1.07-1.19]), whereas in new-onset HF, the rate of 
the composite endpoint was lower in patients with AF compared with those without (HR 0.91 [95% 
CI, 0.85-0.96]) (P-value for interaction < 0.001). 
Conclusions: Among patients hospitalized with decompensated HF, worsening of chronic HF was 
associated with poorer outcomes compared with new-onset HF. 
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Introduction 
Heart failure (HF) is a leading cause of morbidity and mortality worldwide and carries a prognosis 
similar to many cancers.1-3 Advances in the treatment of chronic HF during the past three decades 
have led to significant improvements in prognosis and life expectancy.4 However, despite substantial 
efforts to improve outcomes of patients hospitalized with decompensated HF, numerous clinical 
randomized trials evaluating the efficacy of novel pharmacological therapies and management 
strategies have failed to show benefit.5-14 Hospitalization with decompensated HF represents a 
clinically heterogeneous syndrome, and the paucity of novel therapies may partly be attributed to the 
marked heterogeneity in patient characteristics and etiology. Thus, there is a need to better 
characterize patients hospitalized with HF and their subsequent outcomes. 
Patients presenting with new-onset HF and worsening of chronic HF represent two 
distinct groups among those hospitalized with HF. However, there has been little investigation of 
how these groups compare with respect to their characteristics and subsequent outcomes.15-17 Indeed 
it is not clear what outcomes might be expected a priori. For example, patients with worsening of 
chronic HF might carry a better prognosis than patients with new-onset HF because they have 
survived an initial vulnerable phase after diagnosis.18, 19 Alternatively, longer duration of HF 
disease, with extended exposure to neurohormonal activation and greater maladaptive cardiac 
remodeling, may be associated with higher mortality than that faced after the initial HF diagnosis.19-
21 Understanding the characteristics and outcomes of these two distinct subpopulations may have 
important implications for clinical risk stratification and future trial design. Consequently, we 
examined the clinical characteristics and rates of all-cause mortality and readmissions in an 
unselected, nationwide, and contemporary cohort of patients hospitalized with HF, stratifying as to 





All citizens in Denmark are assigned a unique and personal identification number, which allows 
accurate linkage of nationwide administrative registries at an individual level. For this study, data 
from several nationwide administrative registries were obtained. The Danish National Patient 
Registry holds information on all hospital admissions and outpatient contacts according to the 
International Classification of Diseases (ICD) and all surgical procedures according to the 
NOMESCO Classification of Surgical Procedures.22 The Danish National Prescription Registry 
comprises detailed information on dispensing date, strength, and quantity on all claimed drug 
prescriptions in Denmark.23 The Danish Civil Registration System contains data on birth date, sex, 
and vital status (i.e. whether a person is alive and resident in Denmark, disappeared [persons whose 
residence is unknown to Danish authorities], emigrated, or dead, along with the date of these 
events).24 The Danish Registry of Causes of Death holds information about the date, place, and 
manner of death, as well as the underlying cause.25 
 
Study population 
The study population comprised all Danish citizens with a hospital admission for HF, defined as a 
primary discharge diagnosis of HF, with an overnight hospital stay between January 1, 2013 and 
December 31, 2015. Each patient was included the time of the first hospital admission for HF 





The duration of HF was determined using in-hospital and out-patient diagnosis codes up to 10 years 
prior to admission. Based on the duration of HF, patients were assigned to the following groups: 
New-onset HF, defined as either no history of HF or a history of HF of 30 days or less, and 
worsening of chronic HF, defined as a history of HF of more than 30 days. The latter group was 
further classified into 2 categories according to the duration of HF, 31 days to 3 years and more than 
3 years. These cutoffs were chosen based on the distribution of HF duration within the study 
population and a clinical judgment. 
 
Covariates 
Comorbidity was obtained using in-hospital and out-patient diagnosis codes up to 10 years prior to 
admission (eTable 1 for ICD-10 codes). Patients with diabetes were identified using claimed drug 
prescriptions as described previously.26, 27 Pharmacotherapy at baseline was defined as claimed 
prescriptions within 180 days prior to admission (eTable 2 for ATC codes). 
 
Outcomes 
The primary outcome was a composite of all-cause mortality or HF readmission. Secondary 
outcomes were all-cause mortality, HF readmission, and readmission for any cause. A readmission 
was defined as a hospital admission with an overnight hospital stay. Patients were followed from the 
date of admission until occurrence of the outcome of interest, death, emigration, or end of the study 
(December 31, 2016), whichever came first. 
 
Statistics 
Descriptive data were reported as frequencies with percentages, medians with 25th-75th percentiles. 
Differences in baseline characteristics between patients admitted with new-onset and worsening of 
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chronic HF and between subgroups of worsening of chronic HF were tested with the Chi-squared 
test for categorical variables and the Mann-Whitney test for continuous variables. Survival curves of 
the composite endpoint of HF readmission or all-cause mortality and all-cause mortality according 
to groups were estimated with the Kaplan Meier method, and differences between groups were 
assessed using the log-rank test. The absolute risk of a HF readmission and readmission for any 
cause according to groups was estimated using the Aalen-Johansen estimator and differences 
between groups were assessed using Gray’s test.28 Multivariable Cox regression was used to 
estimate outcome-specific hazard ratios (HR) with 95% confidence intervals (CI). The models were 
adjusted for age (categorical variable: <65, 65-74, 75-81, >82 years), sex, history of ischemic heart 
disease, atrial fibrillation (AF), stroke, diabetes, chronic kidney disease, chronic obstructive 
pulmonary disease, and cancer. Patients admitted with new-onset HF served as the reference group 
in all analyses. Only the first event was considered in patients experiencing multiple events. 
Prespecified subgroup analyses of outcomes were performed for the following variables: Age, sex, 
ischemic heart disease, stroke, AF, and diabetes. In a supplementary analysis, multivariable logistic 
regression, adjusted for the same covariates as in the Cox regression models, were used to estimate 
the odds of in-hospital mortality. Further, multivariable Cox regression were used to examine the 
rates of the primary endpoint among patients discharged alive. In this analysis, patients were 
followed from the date of discharge. All statistical analyses were performed with SAS statistical 
software (SAS 9.4, SAS Institute, Cary, North Carolina, USA). The level of statistical significance 




The Danish Data Protection Agency approved this study (No. 2007-58-0015; internal reference: 
GEH-2014-014, I-Suite no. 02732). In Denmark, registry-based studies, in which individuals cannot 
be identified, do not require ethical approval. 
 
Results 
From January 1, 2013 to December 31, 2015, 17,176 patients had at least one hospital admission for 
HF in Denmark. Of these, 8,860 (51.6%) were admitted with new-onset HF and 8,316 (48.4%) with 
worsening of chronic HF. The median age of the study population was 76 years (25th-75th percentile, 
67-84) and 62.9% were men. The baseline characteristics of the patients in the groups of interest are 
summarized in Table 1. Patients admitted with worsening of chronic HF were more often men, had a 
greater prevalence of cardiovascular and non-cardiovascular comorbidities, and a higher utilization 
of medication compared with those admitted with new-onset HF. 
 
Primary outcome 
The risk of the primary composite endpoint of HF readmission or all-cause mortality according to 
duration of HF is shown in Figure 1a. Worsening of chronic HF was associated with a higher rate of 
the composite endpoint compared with new-onset HF (unadjusted HR 1.54 [95% CI, 1.48-1.60]; 
adjusted HR 1.37 [95% CI, 1.31-1.43]). There was a graded relationship between HF duration and 
the rate of the primary endpoint, with longer duration associated with a higher rate (Figure 2). 
 
Secondary outcomes 
Figure 1b-d displays the risks of all-cause mortality, HF readmission, and readmission for any cause, 
respectively, according to HF duration. Worsening of chronic HF was associated with a higher rate 
of all-cause mortality (unadjusted HR 1.37 [95% CI, 1.31-1.44]; adjusted HR 1.22 [95% CI, 1.16-
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1.28]), HF readmission (unadjusted HR 2.13 [95% CI, 2.01-2.27]; adjusted HR 1.81 [95% CI, 1.69-
1.93]), and readmission for any cause (unadjusted HR 1.34 [95% CI, 1.29-1.39]; adjusted HR 1.18 
[95% CI, 1.13-1.22]) compared with new-onset HF. There was a graded relationship between HF 
duration and the rate of death, HF readmission, and readmission for any cause, as for the primary 
outcome (Figure 2). The number of all HF readmissions during follow-up according to HF duration 
is displayed in eTable 3. Among patients who had a HF readmission during follow-up, the median 
time to first HF readmission was 128 days (25th-75th percentile, 42-340 days) in the new-onset HF 
group and 123 days (25th-75th percentile, 43-345 days) in the worsening of chronic HF group. 
 
Subgroup analysis 
The results of the prespecified subgroup analyses for the primary composite outcome are displayed 
in Figure 3 and for the secondary outcomes in eTable 4. In all subgroups, worsening of chronic HF 
was associated with a higher rate of the composite endpoint of all-cause mortality or HF readmission 
compared with new-onset HF. There was an interaction between AF, HF duration, and and the 
primary outcome: In worsening of chronic HF, the rate of the composite endpoint was higher in 
patients with AF compared with those without (unadjusted HR 1.02 [95% CI, 0.96-1.08]; adjusted 
HR 1.12 [95% CI, 1.07-1.19]), whereas in new-onset HF, the rate of the composite endpoint was 
lower in patients with AF compared with those without (unadjusted HR 1.20 [95% CI, 1.14-1.27]; 
adjusted HR 0.91 [95% CI, 0.85-0.96]) (P-value for interaction < 0.001). This interaction was also 
present for the secondary outcomes (eTable 4). In addition, there was an interaction between age, 
HF duration, and the primary outcome: Age above the median age, as compared with age below the 
median age, was associated with a higher rate of the composite endpoint in both new-onset HF 
(unadjusted HR 2.16 [95% CI, 2.03-2.30]; adjusted HR 2.09 [95% CI, 1.96-2.23]) and worsening of 
chronic HF (unadjusted HR 1.61 [95% CI, 1.53-1.70]; adjusted HR 1.56 [95% CI, 1.47-1.64]), but 
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the association was significantly stronger in the new-onset HF group (P-value for interaction < 
0.001). This interaction was also present for the secondary outcomes except for HF readmission 
(eTable 4). In addition, the interaction with age was also present for all outcomes when age was 
computed as a continuous variable and a categorical variable in the Cox regression models (P-value 
for interaction < 0.001). Figure 4 depicts the risk of the primary outcome according to HF duration 
and AF. eFigure 1 displays the risk of the primary outcome according to HF duration and age. 
 
In-hospital mortality and post-discharge outcomes 
In-hospital mortality was 6.4% (N=570) and 6.9% (N=577) in patients with new-onset and 
worsening of chronic HF, respectively. Worsening of chronic HF was associated with a similar in-
hospital mortality compared with new-onset HF (unadjusted OR 1.08 [95% CI, 0.96-1.22]; adjusted 
OR 1.01 [95% CI, 0.89-1.15]). 
The risks of the composite endpoint and all-cause mortality according to HF duration 
among those discharged alive are shown in eFigure 2a-b. Worsening of chronic HF was associated 
with a higher rate of the composite endpoint (unadjusted HR 1.61 [95% CI, 1.54-1.68]; adjusted HR 
1.41 [95% CI, 1.35-1.48] and all-cause mortality (unadjusted HR 1.43 [95% CI, 1.36-1.50]; adjusted 
HR 1.25 [95% CI, 1.19-1.32]) compared with new-onset HF. 
 
Sensitivity analyses 
A number of sensitivity analyses were performed to test the robustness of our findings: 1) We 
restricted the definition of new-onset HF from a history of HF of 30 days or less to no history of HF. 
Thus, new-onset HF was defined as patients who were diagnosed with HF for the first time at the 
time of admission. In line with the main analysis, worsening of chronic HF was associated with a 
higher rate of the composite endpoint (unadjusted HR 1.71 [95% CI, 1.64-1.78]; adjusted HR 1.49 
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[95% CI, 1.42-1.56]) and all-cause mortality (unadjusted HR 1.54 [95% CI, 1.47-1.61]; adjusted HR 
1.33 [95% CI, 1.27-1.40]) compared with new-onset HF. 2) We restricted the worsening of chronic 
HF population to patients who had at least one hospitalization and found a similar association as the 
main analysis with respect to the composite endpoint (unadjusted 1.52 [95% CI, 1.46-1.58]; adjusted 
HR 1.36 [95% CI, 1.30-1.42]) and all-cause mortality (unadjusted 1.34 [95% CI, 1.28-1.40]; 
adjusted HR 1.20 [95% CI, 1.14-1.26]). 3) We examined the risk of cardiovascular (defined as a 
cardiovascular diagnosis code according to ICD-10 codes: I01-I99) and non-cardiovascular death 
according to HF duration. The absolute risk of cardiovascular and non-cardiovascular death, 
respectively, are displayed in eFigure 3a and 3b. Compared with new-onset HF, worsening of 
chronic HF was associated with a significantly higher rate of cardiovascular death (adjusted HR 
1.35, 95% CI [1.26-1.44]), but not non-cardiovascular death (adjusted HR 1.06, 95% CI [0.98-
1.14]). 4) We examined the relationship between HF duration, modelled as a continuous variable 
(30-day intervals), and the rate of the composite endpoint. Increasing duration of HF was associated 
with a higher rate of the composite endpoint (unadjusted HR 1.004 [95% CI, 1.003-1.004]; adjusted 
HR 1.002 [95% CI, 1.002-1.003]). 
 
Discussion 
In this cohort study of all patients admitted to hospital in Denmark with HF in a three-year period, 
we examined the rates of all-cause mortality and readmission, individually and as a composite, 
according to HF duration. Specifically, we compared patients presenting with new-onset HF to those 
with a diagnosis before admission. Our study yielded 4 major findings: First, patients admitted with 
worsening of chronic HF were more often men and had a greater prevalence of cardiovascular and 
non-cardiovascular comorbidities compared to those presenting with new-onset HF. Second, despite 
a similar in-hospital mortality, worsening of chronic HF was associated with a higher rate of the 
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composite endpoint of all-cause mortality or HF readmission, all-cause mortality, and HF 
readmission during follow-up compared with new-onset HF. Third, there was a graded relationship 
between increasing HF duration and the rate of these outcomes, with longer duration of HF 
associated with higher rates. Fourth, there was an interaction between duration of HF, heart rhythm 
and outcomes. In patients with worsening of chronic HF, outcomes were worse in patients with AF 
compared with those without. In patients with new-onset HF, outcomes were better in patients with 
AF. 
In the ACEND-HF trial (Acute Study of Clinical Effectiveness of Nesiritide in 
Decompensated Heart Failure), 27% of patients hospitalized with HF presented with new-onset or 
recently diagnosed HF (defined as a HF duration of less than 4 weeks),15 while observational studies 
have reported proportions up to 50%.16, 17 In line with these studies, we found that approximately 
50% of patients hospitalized with HF presented with new-onset HF. 
Little attention has been paid to understanding the potential implications of the 
duration of HF on clinical characteristics and prognosis in patients hospitalized with HF. The only 
other substantial information comes from a post-hoc analysis of the 5,741 patients enrolled in 
ASCEND-HF. Patients presenting with worsening of chronic HF (defined as a HF duration of at 
least 4 weeks) had a higher 180-day rate of all-cause mortality compared with those presenting with 
new-onset or recently diagnosed HF.15 However, a limitation of this analysis was the exclusion of 
approximately 20% of the ASCEND-HF population due to lack of data on the date of the HF 
diagnosis. Patients participating in randomized trials are also selected and in ASCEND-HF there 
was not a clear, graded relationship between HF duration and outcomes among patients presenting 
with worsening of chronic HF. We are only aware of two small observational studies, which are 
both limited by absence of data on the duration of HF.16, 17 In each of these other studies, patients 
with worsening of chronic HF in general were more comorbid and had worse baseline kidney 
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function compared with those with new-onset HF. To our knowledge, our study is the first to 
examine the long-term risk of both all-cause mortality and readmissions in a large unselected 
nationwide and contemporary cohort of patients hospitalized with HF according to HF duration. 
Patients presenting with worsening of chronic HF were more often men and had a greater 
comorbidity burden despite a 1-year age difference compared with those admitted with new-onset 
HF. However, even after rigorous adjustment for age, sex, and several comorbidities, we found that 
worsening of chronic HF was associated with higher rates of all-cause mortality and HF readmission 
when compared with new-onset HF. Considering the marked heterogeneity in patients 
characteristics and event rates, a distinction between new-onset and worsening of chronic HF should 
be considered when designing future trials in hospitalized HF. It is possible that duration of HF may 
influence the efficacy of an investigational drug. This notion is supported by the post-hoc analysis of 
ASCEND-HF, which revealed that patients with longer duration of HF were more likely to have 
persisting dyspnea at 24 hours than patients with recently diagnosed HF.15 
An interesting finding in the present study was the graded relationship between HF 
duration and rates of all-cause mortality and HF readmission. Although this finding may seem 
intuitive due to the greater comorbidity burden of patients with longstanding HF, the association 
between increasing HF duration and subsequent risk of outcomes was independent of age and 
comorbidities. Instead, the relationship may be due to prolonged exposure to neurohormonal 
activation and greater maladaptive cardiac remodeling and may reflect the natural course of the 
disease. However, our findings contrast with those of ASCEND-HF, where this graded relationship 
was not found.15 The reasons for this are not clear but may include important differences in patient 
characteristics including age (mean age 65 years in ASCEND-HF), ethnicity, and prevalence of 
diabetes, hypertension, and previous myocardial infarction. 
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Another interesting finding of this study was the interaction between duration of HF, 
heart rhythm and outcomes. In patients with worsening of chronic HF, outcomes were worse in 
patients with AF compared with those without, whereas outcomes were better in patients with new-
onset HF and AF. It is well-known that AF is both a cause and a consequence of HF. HF facilitates 
the initiation and maintenance of AF by several mechanisms, including neurohormonal imbalance 
and activation of the renin-angiotensin-aldosterone system, increased filling pressures and afterload, 
atrial stretch and fibrosis, and dysregulation of calcium homeostasis.29, 30 On the other hand, AF 
promotes the development of HF by a number of mechanisms, including loss of atrial systole which 
impairs left ventricular filling and decreases cardiac output, particularly in patients with diastolic 
dysfunction, and irregular or rapid ventricular conduction which may lead to left ventricular 
dysfunction and tachyarrhythmia-induced cardiomyopathy.29, 30 The finding that patients with new-
onset HF and AF have better outcomes than those without AF may reflect that HF hospitalization to 
a higher degree is a consequence of AF in patients with new-onset HF than in those with worsening 
of chronic HF and that appropriate rate or rhythm control in tachyarrhythmia-induced HF may 
improve hemodynamics and myocardial function and thus subsequent outcomes. 
We also found that the association between HF duration and the rates of subsequent 
outcomes was significantly stronger in younger patients compared with older patients. It is possible 
that this association may in part be explained by the longer life expectancy in younger patients in 
general. Therefore, HF duration in older patients who presumably have a shorter life expectancy 
may be of less importance. 
 
Clinical implications 
The present study demonstrates significant differences between patients admitted with new-onset 
HF as compared to worsening of chronic HF. Despite a similar in-hospital mortality, the long-term 
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rates of adverse events were higher in patients presenting with worsening of chronic HF. These 
findings may have important implications for future clinical trial design and underline that patients 
with worsening of chronic HF should receive even more attention after discharge. However, 
continued efforts to further improve outcomes in patients with worsening of chronic HF should not 
only focus on a greater adoption to guideline-directed medical therapy in outpatient clinics, but also 
on initiation of these agents during hospitalization.31, 32 
 
Strengths and limitations 
The main strength of this study is the completeness of data in a large nationwide cohort of patients 
hospitalized with HF followed in a real-world setting. The findings of this study should be viewed in 
the context of a number of limitations. The observational nature precludes the assessment of cause-
effect relationships and the possibility of residual confounding cannot be excluded despite 
adjustment for potential confounders. Although the Danish administrative registries are validated 
and of high quality with high positive predictive values for the HF diagnosis and other diseases, our 
findings rely on the coding in these registries. Data on important clinical parameters, such as 
natriuretic peptides, estimated glomerular fraction, and other laboratory measurements, vital signs, 
body mass index, and smoking habits, as well as symptoms, including New York Heart Association 
functional class, were not available. Echocardiographic data (e.g. left ventricular ejection fraction, 
left ventricular mass) at baseline or during follow-up were also not available. Thus, a differentiation 
between HF with reduced and preserved ejection fraction was not possible and the degree of cardiac 
recovery during follow-up could not be assessed. Further, the cause-specific mortality analysis is 
dependent on the classification of causes of death, and the quality of the data relies mainly upon the 
correctness of the physicians’ notification. Finally, it is difficult to determine the exact cause for HF 
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readmissions in administrative registries, i.e. whether it reflects a true deterioration of the disease, 
lack of compliance, or occurrence of e.g. AF or an ischemic event. 
 
Conclusions 
In this nationwide cohort study including an unselected contemporary cohort of patients hospitalized 
with HF, worsening of chronic HF was associated with poorer outcomes compared with new-onset 
HF. These findings may have important implications for risk stratification and future clinical trial 
design. 
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Figure legends 
Figure 1. Absolute risk of outcomes according to duration of heart failure 
Figure 1a. Composite of all-cause mortality or heart failure readmission 
Figure 1b. All-cause mortality 
Figure 1c. Heart failure readmission 
Figure 1d. All-cause readmission 
 
Figure 2. Adjusted hazard ratios of outcomes according to duration of heart failure 
 
Figure 3. Adjusted hazard ratios of the composite of all-cause mortality or heart failure 
readmission for worsening versus new-onset HF within subgroups 
CI, confidence interval; DOAC, direct oral anticoagulants; VKA, vitamin K antagonists. 
 
Figure 4. Absolute risk of the primary outcome according to HF duration and rhythm 
